OA20659A - Chimeric filovirus vaccines. - Google Patents
Chimeric filovirus vaccines. Download PDFInfo
- Publication number
- OA20659A OA20659A OA1202200087 OA20659A OA 20659 A OA20659 A OA 20659A OA 1202200087 OA1202200087 OA 1202200087 OA 20659 A OA20659 A OA 20659A
- Authority
- OA
- OAPI
- Prior art keywords
- sequence
- protein
- seq
- flavivirus
- virus
- Prior art date
Links
- 241000711950 Filoviridae Species 0.000 title claims abstract description 28
- 108091006028 chimera Proteins 0.000 title claims abstract description 27
- 229960005486 vaccines Drugs 0.000 title description 39
- 241000700605 Viruses Species 0.000 claims abstract description 52
- 241000710831 Flavivirus Species 0.000 claims abstract description 46
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 39
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 39
- 229920000023 polynucleotide Polymers 0.000 claims abstract description 33
- 239000002157 polynucleotide Substances 0.000 claims abstract description 33
- 101700021629 VEMP Proteins 0.000 claims abstract description 23
- 101700054919 VGE Proteins 0.000 claims abstract description 23
- 101710026800 lyc Proteins 0.000 claims abstract description 23
- 101700003508 pgtE Proteins 0.000 claims abstract description 23
- 230000002238 attenuated Effects 0.000 claims abstract description 15
- 230000002458 infectious Effects 0.000 claims abstract description 12
- 241001115402 Ebolavirus Species 0.000 claims description 25
- 241000710772 Yellow fever virus Species 0.000 claims description 13
- 241000710886 West Nile virus Species 0.000 claims description 12
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 3
- 229940051021 yellow-fever virus Drugs 0.000 claims description 3
- 101710026336 S5 Proteins 0.000 abstract description 7
- 229920001850 Nucleic acid sequence Polymers 0.000 abstract description 2
- 108010086473 Flavivirus NS1 protein Proteins 0.000 abstract 1
- 229920001204 Intergenic region Polymers 0.000 abstract 1
- 108091006011 G proteins Proteins 0.000 description 33
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 33
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 229940024606 Amino Acids Drugs 0.000 description 20
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 20
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 108091007236 Transmembrane domain 2 Proteins 0.000 description 18
- 230000003612 virological Effects 0.000 description 15
- 210000004027 cells Anatomy 0.000 description 13
- 102100016472 GP2 Human genes 0.000 description 12
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- 102100002440 GTPBP1 Human genes 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 241001115401 Marburgvirus Species 0.000 description 8
- 230000000240 adjuvant Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000001580 bacterial Effects 0.000 description 7
- 241001493065 dsRNA viruses Species 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 6
- 101710030378 IFNAR1 Proteins 0.000 description 6
- -1 NS2B Proteins 0.000 description 6
- 108090001123 antibodies Proteins 0.000 description 6
- 102000004965 antibodies Human genes 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000002797 proteolythic Effects 0.000 description 6
- 241000884921 Bundibugyo ebolavirus Species 0.000 description 5
- 102000033147 ERVK-25 Human genes 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 241001115394 Reston ebolavirus Species 0.000 description 5
- 241001115376 Sudan ebolavirus Species 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004436 Chromosomes, Artificial, Bacterial Anatomy 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 101700086956 IFNG Proteins 0.000 description 4
- 102100016020 IFNG Human genes 0.000 description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 description 4
- 208000004006 Tick-Borne Encephalitis Diseases 0.000 description 4
- 208000003152 Yellow Fever Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 230000001086 cytosolic Effects 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 108010087967 type I signal peptidase Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229940092253 Ovalbumin Drugs 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 210000002845 Virion Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000000977 initiatory Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000439488 Cuevavirus Species 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 108090001126 FURIN Proteins 0.000 description 2
- 208000007136 Filoviridae Infection Diseases 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 241000711557 Hepacivirus Species 0.000 description 2
- 206010053317 Hydrophobia Diseases 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 2
- 201000005805 Murray Valley encephalitis Diseases 0.000 description 2
- 101800001030 Non-structural protein 2A Proteins 0.000 description 2
- 101800001020 Non-structural protein 4A Proteins 0.000 description 2
- 241000682735 Pegivirus Species 0.000 description 2
- 241000682990 Pegivirus A Species 0.000 description 2
- 241000682994 Pegivirus B Species 0.000 description 2
- 241000710778 Pestivirus Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 206010056378 Russian spring-summer encephalitis Diseases 0.000 description 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 description 2
- 206010041896 St. Louis encephalitis Diseases 0.000 description 2
- 241000711973 Vesicular stomatitis Indiana virus Species 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 230000000840 anti-viral Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003362 replicative Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WXNRAKRZUCLRBP-UHFFFAOYSA-N 2-[3-(dioctadecylamino)propyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- 229950010555 AVRIDINE Drugs 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K Aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000000234 Capsid Anatomy 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001217856 Chimpanzee adenovirus Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 229920002839 Cis-regulatory element Polymers 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229960000633 Dextran Sulfate Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 206010014071 Ebola disease Diseases 0.000 description 1
- 206010054261 Flavivirus infection Diseases 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 210000002288 Golgi Apparatus Anatomy 0.000 description 1
- 241000808400 Guereza hepacivirus Species 0.000 description 1
- 241000888618 Hepacivirus B Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241001529916 Hepatitis GB virus B Species 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 229940117681 Interleukin-12 Drugs 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 241000710912 Kunjin virus Species 0.000 description 1
- 241001466978 Kyasanur forest disease virus Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 102100020059 NR1H4 Human genes 0.000 description 1
- 101700077249 NR1H4 Proteins 0.000 description 1
- 101700064960 NS-5 Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000193676 Pegivirus C Species 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102000011587 Polyproteins Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000710884 Powassan virus Species 0.000 description 1
- 108050006987 Poxvirus Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 101710033766 Segment-10 Proteins 0.000 description 1
- 101710026339 Segment-12 Proteins 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940031439 Squalene Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920000401 Three prime untranslated region Polymers 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 241000907517 Usutu virus Species 0.000 description 1
- 101700053022 VGC Proteins 0.000 description 1
- 208000007089 Vaccinia Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 206010048282 Zoonosis Diseases 0.000 description 1
- 208000003558 Zoonosis Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 101700038984 csgA Proteins 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 101700056534 farnesoid X receptors Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001024 immunotherapeutic Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000000185 intracerebroventricular Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 229960000974 live attenuated yellow fever Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical class CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000405 serological Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920006004 single-strand RNA Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a Filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a Flaviviral E protein.
Description
CHIMERIC FILOVIRUS VACCINES
Field of the invention
The invention relates to chimeric Flavivirus based vaccines. The invention further relates to vaccines against filoviruses such as Ebola.
Background of the invention
Currently, there is no licensed prophylaxis ortreatment available against Ebola disease (EVD). The most advanced vaccine candidate against Ebola virus (EBOV) is a recombinant vesicular stomatitis Indiana virus (VSV) vectored vaccine expressing the Ebola glycoprotein (G protein or GP) from Zaïre ebolavirus called rVSV-ZEBOV. In addition to rVSV-ZEBOV and, other approaches that hâve been used to generate a vaccine involve the use of human or chimpanzee adenovirus or modified vaccinia virus Ankara (MVA) as vector to express the Ebola GP.
Although a wide range of approaches had been developed to generate a Ebola vaccine, until now, yellow fever 17D has never been used as vector to engineer an Ebola vaccine.
Most of the main vaccine candidates mentioned above require multiples doses to achieve a potent immune response and get full protection. In addition, the requirement of a cold chain to preserve them poses a significant obstacle to implement these vaccines in the African countries where are required. The ring vaccination with rVSV-ZEBOV which needs to be stored at -80C, showed that might not be practical in the field. Besides, there are outstanding questions regarding the long-term safety and immunogenicity of the vaccine (McWilliams étal. (2019) Cell reports 26, 1718-1726.
Summary of the invention
The présent invention discloses a live-attenuated yellow fever vaccine strain (YFV-17D) as vector to engineer a transgenic vaccine by inserting the Ebola glycoprotein (GP) from Makona strain between YF-E/NS1 as follows: the Nterminal (Nt) signal peptide (SP) of Ebola-GP was deleted, the first 9 amino acids of NSI (27 nucléotides) were added Nt of Ebola-GP to allow proper release of Ebola-GP protein, the Ebola-GP cytoplasmatic domain was preserved and fused to the WNV transmembrane domain 2. The resulting plasmid launches viable live-attenuated viruses expressing functional Ebola-GP and YFV17D proteins. The plasmid is thermostable and can be used directly as vaccine, or as stable seed for production of a similar live vaccine in tissue culture or comparable substrate following transfection of said construct. The vaccine induced immune response against both Ebola and YFV after one-single shot. In addition, a second construct was generate in the same way but, in this case, the mucin like domain (MLD) of GP1 was deleted. Also constructs carrying the glycoprotein genes from different filoviruses (BDBV, SUDV, TAFV, RESTV, MARV, RAVV and MLAV) are being generated.
The present invention provides vaccine inducing Fiavivirus (e.g. YFV) and filovirus (e.g. Ebola) virus spécifie immunity. The constructs can also be used as stable seed for the production of tissue culture-derived live-attenuated vaccine. Based on the YFV-Ebola constructs vaccines against other filoviruses (e.g. Marburg virus, MARV) can be generated against which no vaccines exist yes.
The invention is summarised in the following statements:
1. A polynucleotide comprising a sequence of a live, infectious, attenuated Fiavivirus wherein a nucléotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic région between the E and NSI gene of said Fiavivirus, such that a chimeric virus is expressed, characterized in that the encoded sequence C terminally of the E protein of said Fiavivirus and N terminally of the signal peptide of the NSI protein of said Fiavivirus comprises in the following order :
- a further signal peptide of a Fiavivirus NSI protein,
- a filovirus glycoprotein wherein the N terminal signal peptide is absent,
- a TM domain of a flaviviral E protein (typically TM2).
2. The polynucleotide according to statement 1, wherein the mucin like domain (MLD) of the filovirus glycoprotein is absent.
3. The polynucleotide according to statement 1 or 2, wherein the Fiavivirus is Yellow Fever virus, typically the YF17D strain.
4. The polynucleotide according to statement 1 or 2, wherein live, infectious, attenuated Fiavivirus is a chimeric virus.
5. The polynucleotide according to any one of statements 1 to 4, wherein the fiiovirus is a mononegavirus.
6. The polynucleotide according to any one of statements 1 to 5, wherein the fiiovirus is selected from the group consisting of BDBV, SUDV, TAFV, RESTV, MARV, RAVV, MLAV.
7. The polynucleotide according to one of statements 1 to 5, wherein the fiiovirus in an Ebola virus.
8. The polynucleotide according to statement 7, wherein the Ebola virus is the Ebola Makona strain.
9. The polynucleotide according to any one of statements 1 to 8, wherein the nucléotide sequence of the glycoprotein is codon optimized for improved expression in mammalian cells.
10. The polynucleotide according to any one of statements 1 to 9, wherein the signal peptide of the NSI protein of the live, infectious, attenuated Flavivirus, comprises or consists of the sequence DQGCAINFG [SEQ ID NO: 9], 11. The polynucleotide according to any one of statements 1 to 10, wherein the TM2 domain of a flaviviral E protein is from West Nile virus.
12. The polynucleotide according to any one of statements 1 to 11, wherein the TM2 domain of a flaviviral E protein has the sequence RSIAMTFLAVGGVLLFLSVNVHA [SEQ ID NO: 10].
13. The polynucleotide according to any one of statements 1 to 12, wherein the Glycoprotein lacks the N terminal signal sequence of SEQ ID NO 6.
14. The polynucleotide according to any one of statements 1 to 13, wherein the Glycoprotein lacks the mucln like domain of SEQ ID NO:7
15. The polynucleotide according to any one of statements 1 to 13, wherein the sequence of the chimeric virus comprises at the junction of Flavivirus E gene NSI signal peptide and the Ebola glycoprotein the sequence of [SEQ ID NO:11],
16. The polynucleotide according to any one of statements 1 to 14, wherein the sequence of the chimeric virus comprises at the junction of the Ebola glycoprotein and the WNV TM2 domain the sequence of SEQ ID NO: 12].
17. The polynucleotide according to any one of statements 1 to, wherein the sequence of the chimeric virus comprises at the junction of the WNV TM2 domain and the NSI protein the sequence of SEQ ID NO: 13],
In preferred embodiments the junctions connecting the flavirus NSI signal sequence, the Filovirus G protein, the TM protein and the second NSI signal sequence provide a fingerprint for the encoded proteins. Thus embodiments of encoded sequences can be defined by sequences having the sequence of SEQ ID NO:2 or SEQ ID NO: 4, comprising the sequences with SEQ ID NO: 11, SEQ ID: NO: 12 and SEQ ID NO: 13; and wherein outside SEQ ID NO: 11, SEQ ID: NO 12 and SEQ ID NO13 , a number of amino acids may differ from SEQ ID NO:2 or SEQ ID N0:4, e.g. differing up to 20, up to 10, or up to 5 compared to SEQ ID NO:2 or SEQ ID NO: 4, or e.g. having a sequence identity of at least 95 %, 96 %, 97 %, 98% or 99 % with SEQ ID NO:2 or SEQ ID NO:4.
18. The polynucleotide according to any one of the statements 1 to 17, which is a bacterial artificial chromosome.
19. A polynucleotide in accordance to any one of statement 1 to 18, for use as a médicament.
20. The polynucleotide for use as a médicament in accordance with statement 19, wherein the médicament is a vaccine.
21. A polynucleotide sequence in accordance to any one of statement 1 to 18, for use in the vaccination against a Filovirus.
22. A chimeric lîve, infectious, attenuated Flavivirus wherein at least a part of a Filovirus glycoprotein is inserted located between the E and NSI protein of said Flavivirus, such that C terminally of the E protein and N terminally of the signal peptide of the NSI protein the virus comprises in the following order :
a) a further signal peptide of a Flavivirus NSI protein,
b) a filovirus glycoprotein protein lacking a functional signal peptide , and c) a TM domain of a flaviviral E protein.
23. A chimeric virus in accordance to statement 22, for use as a médicament. 24. A chimeric virus in accordance to statement 22, for use in the prévention of a filovirus infection.
25. A chimeric virus encoded by a nucléotide in accordance to statement 22, for use in the prévention of a filovirus and in the prévention of the Flavivirus infection.
26. A method of preparing a vaccine against a filovirus infection, comprising the steps of:
- providing a BAC which comprises:
an inducible bacterial ori sequence for amplification of said BAC to more than 10 copies per bacterial cell, and a viral expression cassette comprising a cDNA of a yellow fever filovirus chimeric virus according to any one of statements 1 to 15, and comprising cisregulatory éléments for transcription of said viral cDNA in mammalian cells and for processing ofthe transcribed RNA into infectious RNA virus,
- transfecting mammalian cells with the BAC of step a) and passaging the infected cells,
-validating replicated virus of the transfected cells of step b) for virulence and the capacity of generating antibodies and inducing protection against rabies infection,
- cloning the virus validated in step c into a vector, and
- formulating the vector into a vaccine formulation.
T7. The method according to statement 26, wherein the vector is BAC, which comprises an inducible bacterial ori sequence for amplification of said BAC to more than 10 copies per bacterial cell.
Detailed description
Figure legends
Figure 1: Schematic représentation of 1) PLLAV-YFV17D-Ebola-GP and 2) PLLAV-YFV17D-Ebola-deltaMLD.
Figure 2: A) Plaque phenotype of YFV17D-Ebola-GP compared to YFV17D. B) Virus stability: RT-PCR analysis of the virus samples harvested during serial passaging (in BHK-21J and VeroE6) of the YFV17D-Ebola-GP virus. C+, control positive PLLAV-YFV17D-Ebola-GP; -RT: RT-PCR reaction without reverse transcriptase; RNA: RT-PCR reaction with the virus RNA.
Figure 3: A) Schematic vaccination schedule. Ifnar(-/-) mice (n=5) were intraperitoneal (IP) or subcutaneous (SC) vaccinated with PLLAV-YFV17DEbola-GP (2.5 pg) or YFV17D-Ebola-GP (250 PFU). B) Humoral immune response in Ifnar(-/-) mice 28 days after vaccination with YFV17D-Ebola-GP (LAV) or PLLAV-YFV17D-Ebola-GP. Represented numbers are the amount of animais that show séroconversion according to an indirect immunofluorescence assay (IIFA) against Yellow Fever (Euroimmune) or Ebola (în-house).
Figure 4: Analysis of cellular immunity in vaccinated Ifnar(-/-) mice. A) Représentative IFN-gamma ELISPOT wells after 48 hours of splénocyte stimulation with the indicated antigen. B) Spots per six hundred thousand splénocytes in IFN-gamma ELISPOT after 48 hours stimulation with the indicated antigen. For each mouse, samples were analysed in duplicates and values are normalized by subtracting the number of spots in control wells (ovalbumin stimulated).
Figure 5: A) Schematic vaccination schedule. B) Table showing the Ebola antibody titres in sérum samples harvested at 28 days post-vaccination of ifnar(-/-) mice vaccinated with YFV17D-Ebola-GP. C) Représentative pictures of HEK293T cells transfected with pCMV-Eboia-GP-IRES-GFP construct to express GFP (green) and Ebola GP that was stained in red with a commercial polyclonal antibody against Ebola-GP or with sérum sample from îfnar(-/-) mice vaccinated with YFV17D-Ebola-GP.
Figure 6: Spots per six hundred thousand splénocytes in IFN-gamma ELISPOT after 48 hours of stimulation with the indicated antigen. For each mouse, samples were analysed in duplicates and values are normalized by subtracting the number of spots in control wells (ovalbumin stimulated).
Figure 7: A) Schematic vaccination schedule. B) Analysis of cellular immunity in vaccinated AG 129 mice. Représentative IFN gamma ELISPOT wells after 48 hours of stimulation of splénocytes with the indicated antigen. For each mouse, samples were anaiysed in duplicates and values are normalized by subtracting the number of spots in control wells (ovalbumin stimulated).
The présent invention is exemplified for Yellow Fever virus, but is also applicable using other viral backbones of Flavivirus species such as, but not limited to, Japanese Encephalitis, Dengue, Murray Valley Encephalitis (MVE), St. Louis Encephalitis (SLE), West Nile (WN), Tick-borne Encephalitis (TBE), Russian Spring-Summer Encephalitis (RSSE), Kunjin virus, Powassan virus, Kyasanur Forest Disease virus, Zika virus, Usutu virus, Wesselsbron and Omsk Hémorrhagie Fever virus.
The invention is further applicable to Fiaviviridae, which comprises the genus Flavivirus but also the généra, Pegivirus, Hepacivirus and Pestivirus.
The genus Hepacivirus comprises e.g. Hepacivirus C (hepatitis C virus) and Hepacivirus B (GB virus B)
The genus Pegivirus comprises e.g. Pegivirus A (GB virus A), Pegivirus C (GB virus C), and Pegivirus B (GB virus D).
The genus Pestivirus comprises e.g. Bovine virus diarrhea virus 1 and Classical swine fever virus (previously hog choiera virus).
The Flavivirus which is used as backbone can itself by a chimeric virus composed of parts of different Fiaviviruses.
For example the C and NS1-5 région are from Yellow Fever and the prME région is of Japanese encephalitis or of Zika virus.
The présent invention is exemplified for the G protein of Ebola virus but is also applicable to G proteins of other filoviruses. Filoviruses suitable in the context of the présent invention are Cuevaviruses such as Llovîu cuevavirus (LLOV), Dianloviruses such as Mënglà virus (MLAV), Ebolaviruses such as Bundibugyo Ebolavirus (BDBV), Reston ebolavirus (RESTV), Sudan ebolavirus (SUDV), Taï Forest ebolavirus (TAFV), Zaïre ebolavirus (EBOV), and Marburgviruses such as Marburg virus (MARV) and Ravn virus (RAVV).
The présent invention relates to nucléotide sequence and encoded proteins wherein within the copy DNA (cDNA) or RNA of a Flavivirus a glycoprotein of an fîlovirus is inserted (Also referred to as G protein or GP). The structure and function of Fîlovirus giycoproteins is reviewed for example in Marin étal. (2016) Antiviral Res. 135, 1-14.
The Ebola glycoprotein originates from a GP1,2 RNA transcript which codes for a GPO precursor. mRNAs are then translated into the GPO precursor, which transits through the endoplasmic réticulum and the Golgi apparatus, where it is cleaved by furin-like protease(s) into two proteins, GP1 and GP2. These two proteins together form a trimeric chalice structure made of three GP1 and three GP2 subunits assembled by GP1/GP2 and GP2/GP2 interactions. The bowl of the chalice is shaped by the GP1 subunits, while GP2 organizes and anchors the complex to the membrane. In the trimer, GPl,2s are bound to each other by disulfide bonds
The ectodomain GP1 is constituted of a core protein and a mucin-like domain (MLD), which ts largely glycosylated.
The core of GP1 is subdivided into three domains: the glycan cap, the head, and the base (Lee et al. (2008) Nature 454, 177-182). The glycan cap is the outer part of GP1 forming the chalice. The head supposedly helps structuring the metastable pre-fusion conformation. This part is exposed to the host membrane surface carrying the putative RBS. The base subdomaîn supports the linkage with GP2 and stabilizes the metastable pre-fusion conformation. The trans-membrane GP2 protein anchors the complex to the viral membrane, but also manages virus entry and fusion. Its structure incorporâtes a transmembrane domain, a short cytoplasmic tail, an internai fusion loop defined by a disulfide bound between GP2 Cys511 and Cys556, and two heptad repeat régions (HRR1 and HRR2) surroundîng the fusion peptide. This domain constitutes the unstable pre-fusion conformation of GP2, which rearranges itself at low pH to trigger fusion. To maintain the structure in the pre-fusion State, the GP1 head packs the GP2 hydrophobie fusion peptide and stabilizes GP2.
The constructs of the present invention allow a proper présentation of the encoded insert into the ER and its proteolytic processing.
The invention is now further described for embodiments wherein a Flavivirus is used as backbone and a G protein of Ebola virus as insert.
The high sequence identity between G proteins of different filovlruses présents no problems to the skilled person to identify in related sequences the sequence éléments corresponding to those present in Ebola virus G protein.
Flavivîruses hâve a positive single-strand RNA genome of approximately 11,000 nucléotides in length. The genome contaîns a 5' untranslated région (UTR), a long open-reading frame (ORF), and a 3' UTR. The ORF encodes three structural (capsîd [C], precursor membrane [prM], and envelope [E]) and seven nonstructural (NSI, NS2A, NS2B, NS3, NS4A, ΝΞ4Β, and NS5) proteins. Along with genomlc RNA, the structural proteins form viral particles. The non-structural proteins participate in viral polyproteîn processing, réplication, virion assembly, and évasion of host immune response. The signal peptide at the C terminus of the C protein (C-signal peptide; also called C-anchor domain) régulâtes Flavivirus packaging through coordination of sequential cleavages at the N terminus (by viral NS2B/NS3 protease in the cytoplasm) and C terminus (by host signalase in the endoplasmic reticulum [ER] lumen) of the signal peptide sequence.
The positive-sense singie-stranded genome is translated into a single polyprotein that is co- and post translationally cleaved by viral and host proteins into three structural [Capsid (C), premembrane (prM), envelope (E)], and seven non-structural (NSI, NS2A, NS2B, NS3, NS4A, NS4B, NS5) proteins. The structural proteins are responsible for forming the (spherical) structure of the virion, initiating virion adhesion, internalization and viral RNA release into cells, thereby initiating the virus life cycle. The non-structural proteins on the other hand are responsible for viral réplication, modulation and évasion of immune responses in infected cells, and the transmission of viruses to mosquitoes. The intra- and inter-molecular interactions between the structural and nonstructural proteins play key rôles in the virus infection and pathogenesis.
The E protein comprises at its C terminal end two transmembrane sequences, indicated as TM1 and TM2 in e.g. figure 6.
NSI is translocated into the lumen of the ER via a signal sequence corresponding to the final 24 amino acids of E and is reieased from E at its amino terminus via cleavage by the ER résident host signal peptidase (Nowak étal. (1989) Virology 169, 365-376). The NSI comprises at its C terminal a 89 amino acids signal sequence which contains a récognition site for a protease (Muller & Young (2013) Antiviral Res. 98, 192-208)
The constructs of the présent invention are chimeric viruses wherein an Ebola G protein is inserted at the boundary between the E and NSI protein. However additional sequence éléments are provided N terminally and C terminally of the G protein insert.
The invention relates to polynucleotide comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucléotide sequence encoding at least a part of a filovirus G protein is inserted at the intergenic région between the E and NSI gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminal the NSI protein of said Flavivirus comprises in the following order :
a sequence element allowing the proteolytic processing of the G protein from the E protein by a signal peptidase.
- a G protein wherein the signal peptide said G protein is absent, and optionally the mucin like domain of the G protein is absent, and
- a TM transmembrane of a flavirus, typically a TM2 domain, typically a West Nile virus TM 2 domain
To allow proteolytic processing of the Fiiovirus G protein from the Flavivirus E protein at its aminoterminal end and allow proteolytic processing of the fiiovirus G protein from the Flavivirus NSI protein at its C terminal, sequence éléments are provided which are substrates for a signal peptidase. These can vary in length and in sequence, and can be as short as one amîno acid as shown in Jang et al. cited above. A discussion on suitable récognition sites for sîgnailing proteases is found in Nielsen étal. (1997) Protein Eng. 10, 1-6.
Typically, at the C terminus of the G protein, the signal peptide at the N terminus of the NSI protein will be used (or a fragment which allows proteolytic processing).
Typically, at the N terminus of the G protein, the same signal peptide (or fragment) ofthe NSI protein ofthe Flavivirus backbone is introduced.
The invention equally relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus. Herein a nucléotide sequence encoding at least a part of a fiiovirus G protein is Inserted at the întergenic région between the E and NSI gene of said Flavivirus. Additional sequences are provided such that when the chimeric virus is expressed such that the encoded sequence from the C terminally of the E protein to the N terminus of the signal peptide ofthe NSI protein comprises in the following order:
a further signal peptide (or cleavable fragment thereof) of a Flavivirus NSI gene, C terminal to the E protein and N terminal to the NSI protein.
a fiiovirus G protein comprising a defective functional signal peptide or lacking a functional signal peptide, This G protein is C terminally positioned from a NSI signal peptide. C terminally of the G protein is the sequence of a Flavivirus TM2 transmembrane domain of a Flavivirus. C terminally of this TM2 sequence follows the NSI protein, including its native signal peptide sequence.
Thus, the G protein and the TM2 domain are flanked at N terminus and C terminus by an NSI sequence. In the embodiments disclosed in the examples the protein and DNA sequence of both NSI are identical.
In typical embodiments both NSI signal sequences hâve the sequence DQGCAINFG [SEQ ID NO:9].
The constructs of the présent invention did not show recombination due to the presence of this répétitive sequence. Sequence modifications can be introduced or NSI sequences from different Flavivirus can be used to avoid presence of identical sequences, as long as the encoded peptide remains a target from the protease which processes these NSI N-terminal signal sequences.
In typical embodiments, as disclosed in the examples, the G protein is of Ebola virus, preferably of the Makona strain of Ebola virus.
To facilitate the production of virus in the mammalian hosts, the nucléotide sequence of the G protein is codon optimized.
It is submitted that minor sequence modifications in the G protein and in the C terminal tail can be introduced without loss of function of these sequence éléments.
It has been found that the presence of a functional signal peptide of the G protein results in a sélective pressure whereby a part of the G protein comprising its signal peptide is deleted or mutated. Thus the constructs of the présent invention typically contain a defective G protein signal by partial or complété removal of this sequence or by the introduction of mutations which render the signal protein non-functional .
The TM domain which is located C terminally of the G protein and N terminally of the NSI is generally of a Flavivirus, typically from the E protein, and more typical a TM2 domain of an E protein. In preferred embodiments this TM2 domain of an E protein is from a different Flavivirus than the virus forming the backbone. The examples of présent invention describe the TM2 domain of the E protein of the West Nile virus. This domain has the sequence RSIAMTFLAVGGVLLFLSVNVHA [SEQ ID NO: 10].
In the examples section below and in the schematic représentation ail sequence éléments form a continuous sequence without any intervening sequence éléments. It is submitted that in between these sequence éléments, addîtional amino acids may be présent as long as the localisation of the protein at either the ER lumen or cytosol is not disturbed and proteolytic Processing is maintained.
The above described nucléotide sequence can be that of the virus itself or can refer to a sequence in a vector. A suitable vector for cloning Flavivirus and chimeric version are Bacterial Artificial Chromosomes, as describe in more detail below.
The methods and compounds of the présent invention hâve médicinal application, whereby the virus or a vector encoding the virus can be used to vaccinate against the filovirus which contains the G protein that was cloned in the Flavivirus. In addition, the proteins from the Flavivirus equally provide protection such that the compounds of the présent invention can be used to vaccinate against a Flavivirus and a filovirus using a single virus or DNA vaccine. The use of Bacterial Artificial Chromosomes, and especially the use of inducible BACS as disclosed by the présent inventors in WO2014174078, is particularly suitable for high yield, high quality amplification of cDNA of RNA viruses such as chimeric constructs ofthe présent invention.
A BAC as described in this publication BAC comprises:
- an inducible bacterial ori sequence for amplification of said BAC to more than 10 copies per bacterial cell, and
- a viral expression cassette comprising a cDNA of an the RNA virus genome and comprising cis-regulatory éléments for transcription of said viral cDNA in mammalian cells and for processing of the transcrîbed RNA into infectious RNA virus.
As is the case in the présent invention the RNA virus genome is a chimeric viral cDNA construct of an RNA virus genome and a filovirus G protein .
In these BACS, the viral expression cassette comprises a cDNA of a positivestrand RNA virus genome, and typically a RNA polymerase driven promoter precedîng the 5' end of said cDNA for initiating the transcription of said cDNA, and an element for RNA self-cleaving following the 3' end of said cDNA for cieaving the RNA transcript of said viral cDNA at a set position.
The BAC may further comprise a yeast autonomously replicating sequence for shuttling to and maintaining said bacterial artificial chromosome in yeast. An example of a yeast ori sequence is the 2μ plasmid origin or the ARS1 (autonomously replicating sequence 1) or functionally homologous dérivatives thereof.
The RNA polymerase driven promoter of this first aspect of the invention can be an RNA polymerase II promoter, such as Cytomégalovirus Immédiate Early (CMV-IE) promoter, or the Simian virus 40 promoter or functionally homologous dérivatives thereof.
The RNA polymerase driven promoter can equally be an RNA polymerase I or III promoter.
The BAC may also comprise an element for RNA self-cleaving such as the cDNA of the genomic ribozyme of hepatitis delta virus or functionally homologous RNA éléments.
The formulation of DNA into a vaccine préparation is known in the art and is described in detail in for example chapter 6 to 10 of DNA Vaccines Methods in Molecular Medicine Vol 127, (2006) Springer Saltzman, Shen and Brandsma (Eds.) Humana Press. Totoma, NJ. and in chapter 61 Alternative vaccine delivery methods, P 1200-1231, of Vaccines (6th Edition) (2013) (Plotkin et al. Eds.). Details on acceptable carrier, diluents, excipient and adjuvant suitable in the préparation of DNA vaccines can also be found in WO2005042014, as indicated below.
Acceptable carrier, diluent or excipient refers to an addîtional substance that is acceptable for use in human and/or veterinary medicine, with particular regard to immunotherapy.
By way of example, an acceptable carrier, diluent or excipient may be a solid or liquid filler, diluent or encapsulating substance that may be safely used in systemic or topic administration. Depending upon the particular route of administration, a variety of carriers, well known in the art may be used. These carriers may be selected from a group including sugars, starches, cellulose and its dérivatives, malt, geiatine, talc, calcium sulphate and carbonates, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonie saline and salts such as minerai acid salts including hydrochlorides, bromides and suiphates, organic acids such as acétates, propionates and malonates and pyrogen-free water.
A useful reference describing pharmaceutically acceptable carriers, diluents and excipients is Remington's Pharmaceutîcal Sciences (Mack Publishing Co. N. J. USA, (1991)) which is incorporated herein by reference.
Any safe route of administration may be employed for providing a patient with the DNA vaccine. For example, oral, rectal, parentéral, sublingual, buccal, intravenous, intra-articular, intra-muscular, intra-dermal, subeutaneous, in ha lationa I, intraocular, intraperitoneal, intracerebroventricular, transdermal and the like may be employed. Intra-muscular and subcutaneous injection may be appropriate, for example, for administration of immunotherapeutic compositions, proteinaceous vaccines and nucleic acid vaccines. It is also contemplated that microparticle bombardment or electroporation may be particularly useful for delivery of nucleic acid vaccines.
Dosage forms include tablets, dispersions, suspensions, injections, solutions, syrups, troches, capsules, suppositories, aérosols, transdermal patches and the like. These dosage forms may also include injecting or implanting controlled releasing devices designed specifically for this purpose or other forms of implants modified to act additionally in this fashion. Controlled release of the therapeutic agent may be effected by coating the same, for example, with hydrophobie polymers including acrylic resins, waxes, higher aliphatic alcohols, polylactic and polyglycolic acids and certain cellulose dérivatives such as hydroxypropylmethyl cellulose. In addition, the controlled release may be effected by usîng other polymer matrices, liposomes and/or mlcrospheres.
DNA vaccines suitable for oral or parentéral administration may be presented as discrète units such as capsules, sachets or tablets each containing a predetermined amount of plasmid DNA, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water émulsion or a water-in-oil liquid émulsion. Such compositions may be prepared by any of the methods of pharmacy but ail methods include the step of bringing into association one or more agents as described above with the carrier which constitutes one or more necessary ingrédients. In general, the compositions are prepared by uniformly and intimateiy admixing the DNA plasmids with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired présentation.
The above compositions may be administered in a manner compatible with the dosage formulation, and in such amount as is effective. The dose administered to a patient, should be sufficient to effect a bénéficiai response in a patient over an appropriate period of time. The quantity of agent (s) to be administered may dépend on the subject to be treated inclusive of the âge, sex, weight and general health condition thereof, factors that will dépend on the judgement of the practitioner.
Furthermore DNA vaccine may be deiîvered by bacterial transduction as using live-attenuated strain of Salmonella transformed with said DNA plasmids as exemplified by Darji et al. (2000) FEMS Immunol Med Microbiol 27, 341-349 and Cicin-Sain étal. (2003) J Virol 77, 8249-8255 given as reference.
Typically the DNA vaccines are used for prophylactic or therapeutic immunisation of humans, but can for certain viruses also be appiied on vertebrate animais (typically mammals, birds and fish) including domestic animais such as livestock and companion animais. The vaccination is envisaged of animais which are a live réservoir of viruses (zoonosis) such as monkeys, dogs, mice, rats, birds and bats.
In certain embodiments vaccines may include an adjuvant, Le. one or more substances that enhances the immunogenicity and/or efficacy of a vaccine composition However, life vaccines may eventually be harmed by adjuvants that may stimulate innate immune response independent of viral réplication. Non-limiting examples of suitable adjuvants include squalane and squalene (or other oils of animal origin); block copolymers; détergents such as Tween-80; Quill A, minéral oils such as Drakeol or Marcoî, vegetable oils such as peanut oil; Corynebacterium-derived adjuvants such as Corynebacterium parvum; Propionibacterium-derived adjuvants such as Propionibacterium acné; Mycobacterium bovîs (Bacille Calmette and Guérin or BCG); interleukins such as interleukin 2 and interleukin 12; monokines such as interleukin 1; tumour necrosis factor; interférons such as gamma interferon; combinations such as saponin-aluminium hydroxide or Quil-A aluminium hydroxide; liposomes; ISCOMt) and ISCOMATRIX (B) adjuvant; mycobacterial cell wall extract; synthetic glycopeptides such as muramyl dipeptides or other dérivatives; Avridine; Lipid A dérivatives; dextran sulfate; DEAE-Dextran or with aluminium phosphate; carboxypolymethylene such as Carbopol'EMA; acryllc copolymer émulsions such as Neocryl A640; vaccinia or animal poxvirus proteins; sub-viral particle adjuvants such as choiera toxin, or mixtures thereof.
EXAMPLES
Example 1 YFV17D/EBOLA CONSTRUCTS
The Ebola glycoprotein (GP) from Makona strain was inserted between YFE/NS1 to generate two constructs as follows:
1) PLLAV-YFV17D-Ebola-GP: N-terminal (Nt) signal peptide (SP) was deleted, first 9 aminoacids of NSI (27 nucléotides) were added Nt of Ebola-GP to allow proper release of Ebola-GP protein, the Ebola-GP cytoplasmic domain was preserved and fused to the WNV transmembrane domain 2. The resulting PLLAV-YFV17D-Ebola-GP launches viable live-attenuated viruses expressing functional Ebola-GP and YFV17D proteins.
2) PLLAV-YFV17D-Ebola-deltaMLD: This construct is similar to the one described above but, in this case, the mucin like domain (MLD) of GP1 was deleted.
Note: Constructs carrying the glycoprotein genes from different filoviruses (BDBV, SUDV, TAFV, RESTV, MARV, RAVV and MLAV) were generated. In these constructs the corresponding GP gene is inserted in the same way as in PLLAVYFV17D-Ebola-GP described above.
Example 2 CONSTRUCT#1 PLLAV-YFV17D-Eboia-GP
PLLAV-YFV17D-Ebola-GP was transfected into BHK21J cells and typical CPE was observed as well as the virus supernatant harvested from them formed markedly smaller plaques compared to the plaque phenotype of YFV17D (Figure 2A). Therefore, the resulting transgenic virus (YFV17D-Ebola-GP) is further attenuated, and virus yieids were at least 10-fold less compared to YFV17D.
The stability of PLLAV-YFV17D-Ebola-GP was determined by performing RT-PCR to detect the transgene insert in virus samples that were harvested during serial passage of the YFV17D-Ebola-GP (Figure 2B). Sequencing of the RT-PCR products showed that YFV17D-Ebola-GP insert with no mutations can be detected at least until passage 6 in BHK21J cells.
To détermine the immunogenicity of PLLAV-YFV17D-Ebola-GP and the liveattenuated virus (LAV) version Ifnar knockout mice (n=5) were vaccinated with either PLLAV-YFV17D-Ebola-GP or the LAV intraperitoneally or subcutaneously (i.p. and s.c. respectively) (figure 3A). The YFV- and EBOV-specific antîbody responses were quantîfied by indirect immunofluorescence assay (IIFA) and the cell mediated immune response was quantîfied by EliSPOT (Figure 3B and 4). Vaccinated mice were monitored daily for morbidity/mortality and blood was sampled for serological analysis at baseline and with two-week intervals. The results showed that in ail the animais vaccinated (i.p. or s,c.) with the LAV version spécifie binding antibodies were detected against both, YFV and EBOV.
Regarding the mice vaccinated with PLLAV in 3 out of 5 of the mice vaccinated i.p. antibodies were detected against YFV and EBOV (Figure 3B).
The analysis of the T cells immune response (Figure 4) revealed that there was spécifie T cell responses after vaccination with YFV17D-Ebola-GP LAV (i.p. and s.c.) and the PLLAV version when his one was inoculated i.p. These results suggests that this is a bivalent vaccine that can induce dual immunity and protection against YFV and EBOV.
In a second experiment (figure 5A), ifnar mice (n = 10) were vaccinated with YFV17D-Ebola-GP (250 PFU) and the spécifie antibody response against EBOV was determined by an in-house IIFA (Figure 5C) (HEK293T cells were transfected with pCMV-Ebola-GP-IRES-GFP construct). The cellular immune response (IFN-gamma ELISPOT) was also analysed (Figure 6). The results in figure 5A shows that in ail animais vaccinated with YFV17D-Ebola-GP there were binding antibodies against EBOV (titres between 1:540 and 1:1620 dilution at 28 days post-vaccination). Ail the animais were seroconverted for YFV as well (data not shown). Concerning, the cellular immune response (figure 6), T cells responses against both, YFV and EBOV, were detected in the mice vaccinated with YFV17D-Ebola-GP. In ail the control mice, vaccinated with YFV17D, as expected, only T cells responses against YFV were observed.
A third experiment evaluated the immune response in AG129 mice after vaccination with either PLLAV-YFV17D-Ebola-GP or its derived LAV (Figure 7A)). The cell mediated immune response was evaluated at 28 days post infection by ELISpot (figure 7B). In ail the mice vaccinated with LAV there was T cells responses against YFV and EBOV. However only in 1 out of 3 mice vaccinated with the PLLAV version a cellular immune response against YFV was observed but not against EBOV. Likely the plasmid was not deliver efficiently in these mice. Nevertheless induction of immunity by PLLAV-YFV17D-Ebola-GP at least in a fraction of mice, demonstrates in principle that the vaccine has the same antigenicity as the live virus vaccine derived thereof and can induce protection if used in the DNA modality as well.
SEQUENCES DEPICTED IN THE APPLICATION
Construct# 1: PLLAV-YFV17D-EBOLA-GP (signal peptide deleted and cytoplasmic tail fused to WNV-TM2)
- End YF-E (amino acids 1-40)
- first 27 nucleotides/9 amino acids NSI, (amino acids 41-49)
- Ebola-gpl [without signal peptide and sequence ΆΆΑΑΆΆΆ [SEQ ID NO: 14]replaced by aaGaaGaA [SEQ ID NO:15], one extra A added to get the GP transmembrane version of the protein) (amino acids 50-329) - mucin like domain (MLD, 150 aa) / (amino acids 330-479) furin cleavage site between GP1-GP2/EBOLA-GP2/ (amino acids 480693)
- WNV-TM2 (amino acids 694-716)
- Beginning YF-NS1(amino acids 717-768)
SEQ ID NO:1
SEQ ID NO:2
AAGGTCATCATGGGGGCGGTACTTATATGGGTTGGCATCAACACAAGAAACATGACAATG KVIMGAVLIWVGINTRNMTM 20
TCCATGAGCATGATCTTGGTAGGAGTGATCATGATGTTTTTGTCTCTAGGAGTTGGcGCc SMSMILVGVIMMFLSLGVGA 40
GACCAGGGCTGCGCGATAa&TTTCGGTatcccgcttggagttatccacaatagtacatta PQGCAINFGI PLGVIHNSTL· 60 caggttAgtgatgtcgacaaactagtttgtcgtgacaaactgtcatccacaaatcaattg
QVSDVDKLVCRDKLSSTNQL 80 agatcagttggactgaatctcgaggggaatggagtggcaactgacgtgccatctgtgact
RSVGLNLEGNGVATDVPSVT 100 aaaagatggggcttcaggtccggtgtcccaccaaaggtggtcaattatgaagctggtgaa
KRWGFRSGVPPKVVNYEAGE 120 tgggctgaaaactgctacaatcttgaaatcaaaaaacctgacgggagtgagtgtctacca
WAENCYNLEIKKPDGSECLP 140 gcagcgccagacgggattcggggcttcccccggtgccggtatgtgcacaaagtatcagga
AAPDGIRGFPRCRYVHKVSG 160 acgggaccatgtgccggagactttgccttccacaaagagggtgctttcttcctgtatgat
TGPCAGDFAFHKEGAFFLYD 180 cgacttgcttccacagttatctaccgaggaacgactttcgctgaaggtgtcgttgcattt
RLASTVIYRGTTFAEGVVAF 200 ctgatactgccccaagctaagaaggacttcttcagctcacaccccttgagagagccggtc
LILPQAKKDFFSSHPLREPV 220 aatgcaacggaggacccgtcgagtggctattattctaccacaattagatatcaggctacc
NATEDPSSGYYSTTIRYQAT 240 ggttttggaactaatgagacagagtacttgttcgaggttgacaatttgacctacgtccaa
GFGTNETEYLFEVDNLTYVQ 260 cttgaatcaagattcacaccacagtttctgctccagctgaatgagacaatatatgcaagt
LESRFTPQFLLQLNETIYAS 280 gggaagaggagcaacaccacgggaaaactaatttggaaggtcaaccccgaaattgataca
GKRSNTTGKLIWKVNPEIDT 300 acaatcggggagtgggccttctgggaaactaaGaaGaAcctcactagaaaaattcgcagt
TIGEWAFWETKKNLTRKIRS 320 gaagagttgtctttcacagctgtatcaaacggAcccaaaaacatcagtggtcagagtccg
EEL S FTAV Zngpknisgqsp 340 gcgcgaactt.att.ccgacccagagacaaacaaaaaaaatgaagaacacaaaa'tcatggc't artssdpetnttnedhkisia 360 tcagaaaattcatctgcaatggttcaagtgcacagtcaaggaaggaaagatgcagtgtag sens samvqvhsqgrkaavs 380 catctgacaacccttgccacaatctccacgagtcctcaacctaacacaaaaaaaacaggt h 1 t t 1 a t i s t s p g p p t t k t g 400 caggacaacagcacccataatacaccegtgtataaacttgacatctctgaggcaactcaa pdnsthntpvykldiseatq 420 gttggacaacatcaccgtagagcagacaacgacagcacagectccgacactcccccegec 5 vgqhhxradndstasdtppa 440 acgaccgcagccggacccttaaaagcagagaacaccaacacgagtaagagegetgactcc ttaagplkaentntsksads 460 ctggacctcgccaccacgacaâgeccccaaaactacagcgagactgctggcaacaacaac d 1 a t t tspqnyse t a g π π η 480 10 actcatcaccaagataccggagaagagagtgccagcagcgggaagctaggcttaattacc thhqdtgeesassgklglit 500 aatactattgctggagtagcaggactgatcacaggcgggagaaggactcgaagaGAAGTA ntiagvaglitggrRTRREV 520 ATTGTCAATGCTCAACCCAAATGCAACCCCAATTTACATTACTGGACTACTCAGGATGAA 15 IVNAQPKCNPNLHYWTTQDE 540 GGTGCTGCAATCGGATTGGCCTGGATACCATATTTCGGGCCAGCAGCCGAAGGAATTTAC
GAAIGLAWIPYFGPAAEGIY 560 ACAGAGGGGCTAATGCACAACCAAGATGGTTTAA TCTGTGGGTTGAGGCAGCTGGCCAAC
TEGLMHNQDGL ICGLRQLAN 580 20 GAAACGACTCAAGCTCTCCAACTGTTCCTGAGAGCCACAACTGAGCTGCGAACCTTTTCA
ETTQALQLFLRATTELRTFS 600 ATCCTCAACCGTAAGGCAATTGACTTCCTGCTGCAGCGATGGGGTGGCACATGCCACATT
ILNRKAIDFLLQRWGGTCHI 620 TTGGGACCGGACTGCTGTATCGAACCACATGATTGGACCAAGAACATAACAGACAAAATT 25 LGPDCCIEPHDWTKNITDKI 640 GATCAGATTATTCATGATTTTGTTGATAAAACCCTTCCGGACCAGGGGGACAATGACAAT
DQIIHDFVDKTLPDQGDNDN 660 TGGTGGACAGGATGGAGACAA TGGATACCGGCAGGTATTGGAGTTACAGGTGTTATAATT
WWTGWRQWIP A GIGVTGVI I 680 30 GCAGTTATCGCTTTATTCTGTATATGCAAATTTGTCTTTAGGTCAATTGCTATGACGTTT
AVIALFCICKFVF R S I A Μ T F 700 CTTGCGGTTGGAGGAGTTTTGCTCTTCCTTTCGGTCAACGTCCATGCTGATCAAGGATGC
LAVGGVLLFLSVNVHAD Q G C720
GCCATCAACITTGGCAAGAGAGAGCTCAAGTGCGGAGATGGTATCTTCATATTTAGAGAC 35 AINFGKRELKCGDGIFIFRD740
TCTGATGACTGGCTGAACAAGTACTCATACTATCCAGAAGATCCTGTGAAGCTTGCATCA
SDDWLNKYSYYPEDPVKLAS 760 ATAGTGAAAGCCTCTTTTGAAGAA IVKASFEE768
Construct# 2: PLLAV-YFV17D-EBOLA-GP MLD (signal peptide and mucin like domain (MLD, 15 0aa from aa 312 to 4 62 ) deleted, cytoplasmic tail fused to WNV-TM2) End YF-E/ first 27 nucléotides NSI (9 amino acids), (amino acids 45 41-49)
Ebola-gpl: [without signal peptide and sequence ΑΆΆΆΆΆΆ [SEQ ID NO:14] replaced by aaGaaGaA [SEQ ID NO:15], one extra A added to get the GP transmembrane version of the protein): furin cleavage site between GP1-GP2/ (amino acids 50- **) 50 EB0LA-GP2 (amino acids ** - 693) WNV-TM2 : (amino acids 694-716) Beginning YF-NS1 : (amino acids 717-768) SEQ ID NO:3
SEQ ID NO: 4
AAGGTCATCATGGGGGCGGTACTTATATGGGTTGGCATCAACACAAGAAACATGACAATG
KVIMGAVLIWVGINTRNMTM20
TCCATGAGCATGATCTTGGTAGGAGTGATCATGATGTTTTTGTCTCTAGGAGTTGGcGCc
SMSMILVGVIMMFLSLGVGA40
GACCAGGGCTGCGCGATAAATTTCGGTatcccgcttggagttatccacaatagtacatta
DQGCAINFGI PLGVIHNSTL60
Caggttagtgatgtcgacaaactagtttgtcgtgacaaactgtcatccacaaatcaattg
QVSDVDKLVCRDKLSSTNQL80
Agatcagttggactgaatctcgaggggaatggagtggcaactgacgtgccatctgtgact
RSVGLNLEGNGVATDVPSVT 100
Aaaagatggggcttcaggtccggtgtcccaccaaaggtggtcaattatgaagctggtgaa
KRWGFRSGVPPKVVNYEAGE 120
Tgggctgaaaactgctacaatcttgaaatcaaaaaacctgacgggagtgagtgtctacca
WAENCYNLEIKKPDGSECLP 140
Gcagcgccagacgggattcggggcttcccccggtgccggtatgtgcacaaagtatcagga
AAPDGIRGFPRCRYVHKVSG 160
Acgggaccatgtgccggagactttgccttccacaaagagggtgctttcttcctgtatgat
TGPCAGDFAFHKEGAFFLYD 180
Cgacttgcttccacagttatctaccgaggaacgactttcgctgaaggtgtcgttgcattt
RLASTVIYRGTTFAEGVVAF 200
Ctgatactgccccaagctaagaaggacttcttcagctcacaccccttgagagagccggtc
LILPQAKKDFFSSHPLREPV 220
Aatgcaacggaggacccgtcgagtggctattattctaccacaattagatatcaggctacc
NATEDPSSGYYSTTIRYQAT 240
Ggttttggaactaatgagacagagtacttgttcgaggttgacaatttgacctacgtccaa
GFGTNETEYLFEVDNLTYVQ 260
Cttgaatcaagattcacaccacagtttctgctccagctgaatgagacaatatatgcaagt
LESRFTPQFLLQLNETIYAS 280
Gggaagaggagcaacaccacgggaaaactaatttggaaggtcaaccccgaaattgataca
GKRSNTTGKLIWKVNPEIDT 300 acaatcggggagtgggccttctgggaaactaaGaaGaAcctcactagaaaaattcgcagt
TIGEWAFWETKKNLTRKIRS 320 gaagagttgtctttcacagctgtatcaaacactcatcaccaagataccggagaagagagt
EELSFTAVSNTHHQDTGEES 340 gccagcagcgggaagctaggcttaattaccaatactattgctggagtagcaggactgatc
ASSGKLGLITNTIAGVAGLI 360 acaggcgggagaaggactcgaagaGAAGTAATTGTCAATGCTCAACCCAAAÎ’GCAACCCC
TGGRRTRREVIVWAOFKCNF 380
AATTTACATTACTGGACTACTCAGGATGAAGGTGCTGCAATCGGATTGGCCTGGATACCA
NLHYWTTQDEGAAIGLAWI P 400
TATTTCGGGCCAGCAGCCGAAGGAATTTACACAGAGGGGCTAATGCACAACCAAGATGGT
YFGPAAEGI YTEGLMHNQDG 420
TTAATCTGTGGGTTGAGGCAGCTGGCCAACGAAACGACTCAAGCTCTCCAACTGTTCCTG
LICGLRQLA N ETTQALQLFL 440
AGAGCCACAACTGAGCTGCGAACCTTTTCAATCCTCAACCGTAAGGCAATTGACTTCCTG
RA T T E L R TFSILNRKAIDFL 460
CTGCAGCGATGGGGTGGCACATGCCACATTTTGGGACCGGACTGCTGTATCGAACCACAT
LQRNGGTCHILGPDCCIEPH 480
GA TTGGACCAAGAACATAACAGACAAAATTGATCAGATTATTCATGATTTTGTTGATAAA
D W T K N I TDKIDQIIHDFVDK 500
ACCCTTCCGGACCAGGGGGACAATGACAATTGGTGGACAGGATGGAGACAATGGATACCG
TLPDQGDNDNWWTGWRQWIP 520
GCAGGTATTGGAGTTACAGGTGTTATAATTGCAGTTATCGCTTTATTCTGTATATGCAAA
AGIGVTGVIIAVIALFCICK 540 TTTGTCmAGGTCAATTGCTATGACGTTTCTTGCGGTTGGAGGAGTTTTGCTCTTCCTT F V F RS IAMTFLAVGGVLLFL560
TCGGTCAACGTCCATGCTGATCAAGGATGCGCCATCAACTTTGGCAAGAGAGAGCTCAAG S V N V H A D QGCAINFGKRELK580
TGCGGAGATGGTATCTTCATATTTAGAGACTCTGATGACTGGCTGAACAAGTACTCATAC CGDGIFIFRDSDDWLNKYSY 600
TATCCAGAAGATCCTGTGAAGCTTGCATCAATAGTGAAAGCCTCTTTTGAAGAA ÏPEDPVKLASTVKASFEE618
Nucléotide and amino acid sequence of deleted peptide [SEQ ID NO:5 [SEQ ID NO:6]
ATGGGTGTTACAGGAATATTGCAGTTACCTCGTGATCGATTCAAGAGGACATCATTCTTT
MGVTGILQLPRDRFKRTSFF 20 CTTTGGGTAATTATCCTTTTCCAAAGAACATTTTCC
LWVIILFQRTFS 32
Mucin like domain [SEQ ID NO: 7]
NGPKNISGQS PARTSSDPET NTTNEDHKIM ASENSSAMVQ VHSQGRKAAV 50
SHLTTLATIS TSPQPPTTKT GPDNSTHNTP VYKLDISEAT QVGQHHRRAD 100
NDSTASDTPP ATTAAGPLKA ENTNTSKSAD SLDLATTTSP QNYSETAGNN 150
Ebolavirus glycoprotein [SEQ ID NO: 8] mgvtgilqlp rdrfkrtsff Iwviilfqrt fsiplgvihn stlqvsdvdk 50
Ivcrdklsst nqlrsvglnl egngvatdvp svtkrwgfrs gvppkvvnye 100 agewaencyn leikkpdgse clpaapdgir gfprcryvhk vsgtgpcagd 150 fafhkegaff lydrlastvi yrgttfaegv vaflilpqak kdffsshplr 200 epvnatedps sgyysttiry qatgfgtnet eylfevdnlt yvqlesrftp 250 qfllqlneti yasgkrsntt gkliwkvnpe idttigewaf wetkknltrk 300 irseelsfta vsngpknisg qspartssdp etnttnedhk imasenssam 350 vqvhsqgrka avshlttlat istspqpptt ktgpdnsthn tpvykldise 400 atqvgqhhrr adndstasdt ppattaagpl kaentntsks adsldlattt 450 spqnysetag nnnthhqdtg eesassgklg litntiagva glitggrrtr 500 revivnaqpk cnpnlhywtt qdegaaigla wipyfgpaae giyteglmhn 550 qdglicglrq lanettqalq Iflrattelr tfsilnrkai dfllqrwggt 600 chilgpdcci ephdwtknit dridqiihdf vdktlpdqgd ndnwwtgwrq 650 wipagigvtg viiavialfc ickfvf
NSI signal sequence [SEQ ID NO:9] DQGCAINFG
WNV TM2 domain [SEQ ID NO:10] RSIAMT FLAVGGVLL FLSVNVHA junction NSI signal peptide Ebola glycoprotein [SEQ ID NO:11] AINFGIPLGV junction Ebola glycoprotein- WNV TM2 domain [SEQ ID NO:12] CKFVFRSIAM junction TM2 domain - NSI protein [SEQ ID NO:13] VNVHADQGCA
Claims (10)
1. A polynucleotide comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucléotide sequence encoding at least a part of a Filovirus glycoprotein is located atthe intergenic région between the E and NSI gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NSI protein of said Flavivirus comprises in the following order:
- a further signal peptide of a Flavivirus NSI protein,
- a Filovirus glycoprotein wherein the N terminal signal peptide is absent, - a TM domain of a Flaviviral E protein (typically TM2).
2. The polynucleotide according to claim 1, wherein:
- the mucin like domain (MLD) of the Filovirus glycoprotein is absent; and/or
- the glycoprotein lacks the mucin like domain of SEQ ID NO:7; and/or
- the glycoprotein lacks the N terminal signal sequence of SEQ ID NO 6.
3. The polynucleotide according to claim 1 or 2, wherein:
- the Flavivirus is Yellow Fever virus, typically the YF17D strain; and/or
- the Filovirus is a mononegavirus or an Ebola virus.
4. The polynucleotide according to any one of daims 1 to 3, wherein the signal peptide of the NSI protein of the live, infectious, attenuated Flavivirus, comprises or consists of the sequence DQGCAINFG [SEQ ID NO: 9],
5. The polynucleotide according to any one of claims 1 to 4, wherein the TM2 domain of a Flaviviral E protein is from West Nile virus.
6. The polynucleotide according to any one of claims 1 to 5, wherein the sequence of the chimeric virus comprises at the junction of Flavivirus E gene NSI signal peptide and the Ebola glycoprotein the sequence of SEQ
ID NO: 11, or wherein the sequence ofthe chimeric virus comprises at the junction of the Ebola glycoprotein and the WNV TM2 domain the sequence of SEQ ID NO: 12, or wherein the sequence of the chimeric virus comprises at the junction of the WNV TM2 domain and the NSI protein the sequence of SEQ ID NO: 13.
7. The polynucleotide according to any one of daims 1 to 6, encoding a sequence comprising SEQ ID NO: 11, SEQ ID: NO 12 and SEQ ID NO: 13; and outside SEQ ID NO: 11, SEQ ID: NO 12 and SEQ ID NO: 13, a sequence identity of at least 95 %, 96 %, 97 %, 98% or 99 % with SEQ ID NO:2 or SEQ ID NO:4.
8. The polynucleotide according to any one of daims 1 to 7, wherein the encoded sequence comprises the sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
9. A chimeric live, infectious, attenuated Flavivirus wherein at least a part of a Fiiovirus glycoprotein is inserted located between the E and NSI protein of said Flavivirus, such that C terminally of the E protein and N terminally of the signal peptide of the NSI protein the virus comprises in the following order :
a) a further signal peptide of a Flavivirus NSI protein,
b) a Fiiovirus glycoprotein protein lacking a functional signal peptide, and
c) a TM domain of a Flaviviral E protein.
10. A polynucleotide sequence according to any one of claîm 1 to 8, or a chimeric virus according to daim 9, for use in the prévention of a fiiovirus infection.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19197322.1 | 2019-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA20659A true OA20659A (en) | 2022-12-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9217158B2 (en) | Replication-defective flavivirus vaccines and vaccine vectors | |
WO2014093602A1 (en) | Compositions and methods for treating and preventing hepatitis c virus infection | |
AU2018344508B2 (en) | Live-attenuated flaviruses with heterologous antigens | |
US20220402976A1 (en) | Chimeric filovirus vaccines | |
OA20659A (en) | Chimeric filovirus vaccines. | |
US20220168412A1 (en) | Chimeric Zika-Japanese Encephalitis Virus | |
US20220378903A1 (en) | Lassavirus vaccines | |
RU2816136C2 (en) | Chimeric vaccines based on viruses of flavivirus and lyssavirus genes | |
US20210353735A1 (en) | Chimeric Flavivirus Lyssavirus Vaccines | |
OA20740A (en) | Lassavirus vaccines. | |
US11351240B2 (en) | Chimeric yellow fever ZIKA virus strain | |
WO2013116770A1 (en) | Replication-defective flavivirus vaccines and vaccine vectors | |
AU2002360315B2 (en) | Thymosin augmentation of genetic immunization | |
NZ532863A (en) | Thymosin augmentation of genetic immunization for the treatment of hepatitis C | |
AU2002360315A1 (en) | Thymosin augmentation of genetic immunization |